中国临床药学杂志

参考文献

[1]Dalla VM,Simioni N,Masiero A.Aliskiren:a new inhibitor of reninangiotensin aldosterone system activity[J].Minerva Endocrinol,2009, 34(4):333.

[2]Pool JL.Direct renin inhibition:focus on aliskiren[J].J Manag Care Pharm,2007,13(RSuppl B):21.

[3]李华,郭冀珍.阿利吉仑——一种新型肾素抑制剂[J].中国新药与临床杂志,2006(3):216.

[4]Hu P,Bartlett M,Karan RS,et al.Pharmacokinetics,safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects:a randomized,single-blind,parallel-group,placebo-controlled study[J].Clin Drug Investig,2010,30(4):221.

[5]Vaidyanathan S,Warren V,Yeh C,et al.Pharmacokinetics,safety,and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment[J].J Clin Pharmacol,2007,47(2):192.

[6]Nussberger J,Wuerzner G,Jensen C,et al.AngiotensinⅡsuppression in humans by the orally active renin inhibitor aliskiren(SPP100):comparison with enalapril[J].Hypertension,2002,39(1):E1.

[7]Wood JM,Schnell CR,Cumin F,et al.Aliskiren,a novel,orally effective renin inhibitor,lowers blood pressure in marmosets and spontaneously hypertensive rats[J].J Hypertens,2005,23(2):417.

[8]Weir MR,Bush C,Anderson DR.et al.Antihypertensive efficacy,safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension:a pooled analysis[J].J Am Soc Hypertens,2007,1 (4):264.

[9]Weintraub HS,Tran H,Schwartzbard A.Potential benefits of aliskiren beyond blood pressure reductian[J].Cardiol Rev,2011,19(2):90.

[10]van Each JH,Moltzer E,van Veghel R,et al.Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats[J].J Hypertens,2010,28(10):2145.

[11]Dong YF,Liu L,Kataoka K,et al.Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes[J].Diabetologia,2010,53(1):180.

[12]Kelly DJ,Zhang Y,Moe G,et al.Aliskiren,anovel renin inhibitor,is renoprotective in a model of advanced diabetic nephropathy in rats[J]. Diabetologia,2007,50(11):2398.

[13]Nussberger J,Aubert JF,Bouzourene K,et al.Renin inhibition by aliskiren prevents atherosclerosis progression:comparison with irbesartan, atenolol,and amlodipine[J].Hypertension,2008,51(5):1306.

[14]Imanishi T,Tsujioka H,Ikejima H,et al.Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes[J].Hypertension,2008,52(3):563.

[15]Poss J,Werner C,Lorenz D,et al.The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice[J].Basic Res Cardiol,2010,105(6):725.

[16]Kang YS,Lee MH,Song HK,et al.Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice [J].Nephrol Dial Transplant,2011,26(4):1194.

[17]Iwai M,Kanno H,Tomono Y,et al.Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice[J].J Hypertens,2010,28(7):1471.

[18]Lastra G,Habibi J,Whaley-Connell AT,et al.Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression[J].Endocrinology, 2009,150(6):2561.

[19]Drummond W,Munger MA,Rafique EM,et al.Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy[J].J Clin Hypertens (Greenwich),2007,9(10):742.

[20]Persson F,Rossing P,Reinhard H,et al.Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus:a randomised crossover trial [J].Diabetologia,2010,53(8):1576.

[21]Parving HH,Persson F,Lewis JB,et al.Aliskiren combined with losartan in type 2 diabetes and nephropathy[J].N Engl J Med,2008,358 (23):2433.

[22]McMurray JJ,Pitt B,Latini R,et al.Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure[J].Circ Heart Fail,2008,1(1):17.

[23]Solomon SD,Appelbaum E,Manning WJ,et al.Effect of the direct renin inhibitor aliskiren,the angiotensin receptor blocker losartan,or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy[J].Circulation,2009,119(4):530.

[24]Vaidyanathan S.Reynolds C,Yeh CM,et al.Pharmacokinetics,safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects[J].J Clin Pharmacol,2007,47(4):453.

[25]Peitz GJ,Malesker MA,Sojka SG.Aliskiren-induced QT interval prolongation [J].South Med J,2009,102(4):411.

[26]Weir MR,Bush C,Anderson DR,et al.Antihypertensive efficacy, safety,and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension:a pooled analysis[J].J Am Soc Hypertens, 2007,1(4):264.